BPC-157 and TB-500 in Ischaemia-Reperfusion and Cardiac Injury Models: What the Animal Literature Reports

RESEARCH · BPC-157 + TB-500 · ISCHAEMIA-REPERFUSION

BPC-157 and TB-500 in Ischaemia-Reperfusion and Cardiac Injury Models: What the Animal Literature Reports

PurixLab’s BPC-157 + TB-500 10mg is a research vial combining a pentadecapeptide and a thymosin beta-4 fragment. Our earlier articles cover the preclinical evidence and the human data gap, the molecular mechanisms proposed in the literature and gastrointestinal mucosal models. This article looks at one published model family in detail: ischaemia-reperfusion and cardiac injury in animals, where both components have been studied separately and where the negative results are as informative as the positive ones. The material is supplied for laboratory research use only, and nothing here describes effects of any PurixLab product.

What the ischaemia-reperfusion literature covers

A 2026 critical review searched the rodent literature on BPC-157 in ischaemia-reperfusion injury and related reperfusion-associated vascular injury, and reported that across the available studies the peptide has been associated with attenuation of oxidative injury, modulation of nitric oxide-related vascular responses, reductions in inflammatory and apoptotic markers, and changes in VEGF/VEGFR2-Akt-eNOS-related signalling. The author declined to perform a meta-analysis because of substantial heterogeneity in organ systems, injury paradigms, routes, treatment timing and outcome measures, and concluded that current evidence supports the compound as a hypothesis-generating investigational candidate for further preclinical research rather than an established therapy [1].

Limb ischaemia-reperfusion in rats

A representative experiment randomised twenty-four male Wistar albino rats into sham, peptide-only, ischaemia-reperfusion and combined groups, with 45 min of abdominal aortic clamping followed by 2 h of reperfusion. Ischaemia-reperfusion increased malondialdehyde, total oxidant status and transcripts for p53, Bax, Casp3, Hif-1a and Il-6 while reducing superoxide dismutase, total antioxidant status and VEGF expression; in the treated group these changes were attenuated and histological muscle architecture improved. The authors called for larger cohorts and response evaluations before clinical relevance could be established [2]. A companion study from the same group examined distant organs after limb ischaemia-reperfusion and reported lower renal, pulmonary and hepatic histopathological scores and higher antioxidant activity in treated animals [3].

Vascular occlusion and the collateral-pathway hypothesis

A separate line of work frames the effect as vascular rather than cytoprotective. In rats with permanent occlusion of the superior mesenteric artery, treatment was reported to recruit collateral vessels circumventing the occlusion and to attenuate portal and caval hypertension, aortal hypotension, superior sagittal sinus hypertension, ECG disturbances and multiple organ lesions over a 30-min assessment [4]. In isoprenaline-induced myocardial infarction, the same group reported reduced necrosis markers, attenuated gross and histological damage, and preserved systolic left ventricular function, associated with decreased oxidative stress parameters and interaction with eNOS and COX2 gene expression [5]. A review by that group gathers the cardiac claims, including arrhythmia, pulmonary hypertension and thrombosis models, under a single cytoprotection framework [6]. In a hippocampal model using bilateral clamping of the common carotid arteries for 20 min, the authors reported counteraction of early and delayed neural damage with functional recovery on maze and beam-walking tests, alongside altered expression of Egr1, Akt1, Src, Vegfr2 and Nos3 [7]. Much of this body of work originates from one research network, which is itself a limitation noted by the independent review [1].

Thymosin beta-4: a longer and more contradictory record

The TB-500 component corresponds to an actin-binding region of thymosin beta-4, and the parent peptide has been tested in cardiac injury for two decades. The founding report described a functional complex with PINCH and integrin-linked kinase, activation of Akt, enhanced early myocyte survival and improved cardiac function after coronary artery ligation in mice [8]. Subsequent work identified the peptide as essential for coronary vessel development and as a stimulator of adult epicardial explant outgrowth [9], and reported that priming with it labelled adult progenitors that differentiated into cardiomyocytes after infarction [10]. In pigs, retrograde application reduced infarct size and improved segmental shortening, an effect abolished by short hairpin RNA knockdown [11], and adeno-associated-virus-mediated overexpression increased collateralisation and ejection fraction in both normocholesterolaemic and hypercholesterolaemic animals [12].

Against this sit several negative findings. Global and cardiac-specific knockout mice were born at Mendelian ratios with normal hearts and vessels, leading the authors to conclude that the peptide is dispensable for embryonic viability, heart development and adult myocardial function [13]. An attempt to reproduce the progenitor effect in a genetic reporter line found no evidence that the peptide reactivates Islet-1 expression in adult mouse ventricle [14]. In a pig model of global myocardial ischaemia-reperfusion with cardiopulmonary bypass, systemic administration before and after ischaemia did not decrease cell death and cardiac function was similar between groups [15].

Human data and analytical identity

Human evidence exists only for recombinant full-length thymosin beta-4, not for the fragment. A phase I study in healthy volunteers reported adverse events of mild to moderate intensity and no serious adverse events [16], and a 2025 report combined murine ischaemia-reperfusion experiments with a randomised, placebo-controlled trial in 96 patients after percutaneous coronary intervention, where the overall difference in infarcted areas between groups was not significant [17]. On identity, analytical work on material sold as TB-500 identified the N-terminally acetylated 17-23 fragment Ac-LKKTETQ by high-resolution mass spectrometry [18], and an equine study characterised the parent peptide and its metabolites in urine and plasma, confirming the acetylated fragment at 0.01 ng/mL in urine [19]. The fragment and the full-length protein are different analytes, and the cardiac literature above is almost entirely about the latter.

What remains open

  • Replication. The independent review calls for blinded replication, response and therapeutic-window studies and pharmacokinetic characterisation [1].
  • Short observation windows. Rodent reperfusion experiments commonly end hours after the insult [2,3].
  • Contradiction in the thymosin literature. Genetic knockouts and a large-animal reperfusion study did not reproduce protective effects [13,15].
  • No combination studies. We found no ischaemia-reperfusion study testing the two peptides together, so a blend is not covered by either literature [1,6].

BPC-157 + TB-500 10mg at PurixLab

BPC-157 + TB-500 10mg: a labelled lyophilized research vial with BPC-157 5mg + TB-500 5mg per vial (10mg total), C$89 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/bpc-157-tb-500-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View BPC-157 + TB-500 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Demirtaş H. BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence. Int J Mol Sci. 2026;27(18):8344. PubMed 42794771 · PMC13607336 · doi:10.3390/ijms27188344
  2. Yıldırım AK, Demirtaş H, Özer A, et al. Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Sci Rep. 2026;16(1):24375. PubMed 42204242 · PMC13448812 · doi:10.1038/s41598-026-55449-1
  3. Demirtaş H, Özer A, Yıldırım AK, et al. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas). 2025;61(2):291. PubMed 40005408 · PMC11857380 · doi:10.3390/medicina61020291
  4. Knezevic M, Gojkovic S, Krezic I, et al. Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension. Biomedicines. 2021;9(6):609. PubMed 34073625 · PMC8229949 · doi:10.3390/biomedicines9060609
  5. Barisic I, Balenovic D, Udovicic M, et al. Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats. Biomedicines. 2022;10(2):265. PubMed 35203478 · PMC8869603 · doi:10.3390/biomedicines10020265
  6. Sikiric P, Udovicic M, Barisic I, et al. Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation. Biomedicines. 2022;10(11):2696. PubMed 36359218 · PMC9687817 · doi:10.3390/biomedicines10112696
  7. Vukojević J, Vrdoljak B, Malekinušić D, et al. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain Behav. 2020;10(8):e01726. PubMed 32558293 · PMC7428500 · doi:10.1002/brb3.1726
  8. Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-72. PubMed 15565145 · doi:10.1038/nature03000
  9. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-82. PubMed 17108969 · doi:10.1038/nature05383
  10. Smart N, Bollini S, Dubé KN, et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature. 2011;474(7353):640-4. PubMed 21654746 · PMC3696525 · doi:10.1038/nature10188
  11. Hinkel R, El-Aouni C, Olson T, et al. Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation. 2008;117(17):2232-40. PubMed 18427126 · PMC2672916 · doi:10.1161/CIRCULATIONAHA.107.758904
  12. Ziegler T, Bähr A, Howe A, et al. Tβ4 Increases Neovascularization and Cardiac Function in Chronic Myocardial Ischemia of Normo- and Hypercholesterolemic Pigs. Mol Ther. 2018;26(7):1706-1714. PubMed 29929787 · PMC6037200 · doi:10.1016/j.ymthe.2018.06.004
  13. Banerjee I, Zhang J, Moore-Morris T, et al. Thymosin beta 4 is dispensable for murine cardiac development and function. Circ Res. 2012;110(3):456-64. PubMed 22158707 · PMC3739283 · doi:10.1161/CIRCRESAHA.111.258616
  14. Weinberger F, Nicol P, Starbatty J, et al. No effect of thymosin beta-4 on the expression of the transcription factor Islet-1 in the adult murine heart. Pharmacol Res Perspect. 2018;6(3):e00407. PubMed 29864245 · PMC5986028 · doi:10.1002/prp2.407
  15. Stark CK, Tarkia M, Kentala R, et al. Systemic Dosing of Thymosin Beta 4 before and after Ischemia Does Not Attenuate Global Myocardial Ischemia-Reperfusion Injury in Pigs. Front Pharmacol. 2016;7:115. PubMed 27199757 · PMC4853610 · doi:10.3389/fphar.2016.00115
  16. Wang X, Liu L, Qi L, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228. PubMed 34346165 · PMC8419156 · doi:10.1111/jcmm.16693
  17. Zhang Y, Dong Q, Bian X, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025;121(17):2747-2758. PubMed 41229390 · doi:10.1093/cvr/cvaf223
  18. Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027 · doi:10.1002/dta.1402
  19. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed 23084823 · doi:10.1016/j.chroma.2012.09.043

Leave a Comment

Your email address will not be published. Required fields are marked *